Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study by Kathleen M. Wesa et al.
1 3
Cancer Immunol Immunother (2015) 64:237–247
DOI 10.1007/s00262-014-1628-6
ORIGINAL ARTICLE
Maitake mushroom extract in myelodysplastic syndromes (MDS): 
a phase II study
Kathleen M. Wesa · Susanna Cunningham-Rundles · Virginia M. Klimek · 
Emily Vertosick · Marci I. Coleton · K. Simon Yeung ·  
Hong Lin · Stephen Nimer · Barrie R. Cassileth 
Received: 17 February 2014 / Accepted: 8 October 2014 / Published online: 29 October 2014 
© The Author(s) 2014. This article is published with open access at Springerlink.com
neutrophil count and function tested as endogenous or 
stimulated neutrophil production of reactive oxygen spe-
cies (ROS) by flow cytometry compared with age-matched 
healthy controls (HC). ROS activators were Escherichia 
coli, phorbol ester, and the bacterial peptide N-formyl-
methionyl-leucyl-phenylalanine (fMLP). Complete blood 
counts, chemistry panels, iron studies, and monocyte func-
tion were evaluated.
Results Of 21 patients enrolled, 18 completed the study 
and were evaluable. Maitake increased endogenous (basal) 
neutrophil (p = 0.005) and monocyte function (p = 0.021). 
Pre-treatment monocyte response to E. coli was reduced in 
MDS patients compared with HC (p = 0.002) and increased 
(p = 0.0004) after treatment. fMLP-stimulated ROS pro-
duction response also increased (p = 0.03). Asymptomatic 
eosinophilia occurred in 4 patients (p = 0.014). Other 
changes in albumin, hemoglobin, and total protein were not 
clinically relevant.
Conclusions Maitake was well tolerated. Enhanced in 
vitro neutrophil and monocyte function following treatment 
demonstrate that Maitake has beneficial immunomodula-
tory potential in MDS. Further study is warranted.
Keywords Myelodysplastic syndrome · Maitake · Beta-
glucan · Infections · Neutrophil · Monocyte
Abbreviations
AML  Acute myelogenous leukemia
ANC  Absolute neutrophil count
ANOVA  Analysis of variance
CFU-GM  Colony-forming unit-granulocyte/macrophage
CI  Confidence interval




Background Myelodysplastic syndromes (MDS) are char-
acterized by ineffective erythropoiesis with dysplastic bone 
marrow leading to peripheral cytopenia, risk of infection, 
and progression to acute myelogenous leukemia. Maitake 
mushroom beta-glucan, a dietary supplement, stimulates 
hematopoietic progenitor cell differentiation, granulo-
cyte colony-stimulating factor production, and recovery of 
peripheral blood leukocytes after bone marrow injury. This 
phase II trial examined the effects of Maitake on innate 
immune function in MDS.
Methods Myelodysplastic syndromes patients with Inter-
national Prognostic Scoring System Low- and Intermedi-
ate-1-risk disease received oral Maitake extract at 3 mg/
kg twice daily for 12 weeks. Primary endpoints included 
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FAB  French–American–British classification
fMLP  N-formylmethionyl-leucyl-phenylalanine
G-CSF  Granulocyte colony-stimulating factor
GM-CSF  Granulocyte–macrophage colony-stimulating 
factor
HC  Healthy controls
HIV  Human immunodeficiency virus
HPC  Hematopoietic progenitor cells
IL  Interleukin
IPSS  International Prognostic Scoring System
IQR  Interquartile range
IWG  International Working Group
LPS  Lipopolysaccharide
MDS  Myelodysplastic syndromes
MSKCC  Memorial Sloan Kettering Cancer Center
NADPH  Nicotinamide-adenine dinucleotide phosphate
PMA  Phorbol 12-myristate 13-acetate
RBC  Red blood cell
ROS  Reactive oxygen species
SD  Standard deviation
WBC  White blood cell
Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous 
group of clonal bone marrow stem cell disorders charac-
terized by ineffective erythropoiesis with dysplastic bone 
marrow leading to peripheral blood cytopenias and a vari-
able propensity for progression to acute myelogenous leu-
kemia (AML). Neutropenia occurs in 50 % of newly diag-
nosed patients, more frequently in those with higher-risk 
(70–80 %) compared with lower-risk (15–20 %) MDS [1]. 
Pneumonia was identified as the leading cause of death in 
a recent investigation of untreated MDS patients with low 
or intermediate risk. The pathogen was mainly bacterial 
although sometimes fungal or more rarely viral [2]. The 
use of hypomethylating agents and lenalidomide in MDS 
patients will transiently worsen neutropenia and has stimu-
lated investigation into the causes of infection and strate-
gies to reduce risk [1].
Infection has been largely attributed to neutrophil 
dysfunction rather than neutropenia, since early studies 
showed that neither infections nor mortality were related 
to low neutrophil count [3]. A recent study in Asian MDS 
patients using the French–American–British (FAB) classifi-
cation and International Prognostic Scoring System (IPSS) 
confirmed that neutrophil count did not predict prognosis in 
persistent severe neutropenia (neutrophil count < 500 μ/L) 
and that even a neutrophil count <200 μ/L showed only 
borderline prognostic significance [4]. Early studies 
reported that granulocyte function (mainly neutrophils in 
circulation) was reduced across FAB classifications [5]. 
Subsequent investigations revealed variable impairment in 
different neutrophil functions independent of neutrophil 
number, including reduced chemotaxis, decreased adhe-
sion molecule expression, and loss of microbicidal activity, 
especially in patients with recurrent infection [6, 7]. Fuh-
ler et al. identified mechanisms of neutrophil dysfunction 
in MDS as disturbed chemokine receptor-induced response 
and impaired migration of circulating neutrophils toward 
the chemoattractant interleukin-8 (IL-8). Impaired migra-
tion in blood could be traced to defects in early hematopoi-
etic progenitors in bone marrow [8, 9].
Intracellular generation of highly reactive oxygen spe-
cies (ROS) in the respiratory burst pathway is produced by 
the reduced nicotinamide-adenine dinucleotide phosphate 
(NADPH) oxidase complex. ROS activation is triggered by 
receptor-mediated binding of soluble chemotactic agents, 
such as the bacterial peptide N-formyl-methionyl-leucyl-
phenylalanine (fMLP) and receptor-independent phorbol 
ester phorbol-myristate-acetate (PMA). Granulocyte col-
ony-stimulating factor (G-CSF), granulocyte–macrophage 
CSF (GM-CSF), and cytokines prime the ROS response. 
Early studies showed that ROS activity varied in MDS 
patients from normal to abnormal independent of neutro-
phil number [10–12]. Priming with G-CSF and GM-CSF 
could partially enhance fMLP-stimulated ROS activity in 
MDS patients’ neutrophils compared with healthy control 
responses [13]. Subcutaneous administration of GM-CSF 
to MDS patients enhanced neutrophil function, assessed 
ex vivo as microbicidal activity [14]. G-CSF treatment of 
high-risk MDS patients showed a borderline protective 
effect against infections [15]. However, use of GM-CSF 
and G-CSF treatment in MDS has been limited due to con-
cerns about effects on progression, safety, and side effects 
[16].
We recently reported that oral administration of Maitake 
beta-glucan, a dietary supplement, stimulated hematopoie-
sis in bone marrow, recovery of circulating monocyte/
neutrophil numbers, and normalized ROS production com-
pared with no treatment or G-CSF-treatment in a mouse 
model of acute hemotoxic bone marrow injury [17]. Since 
Maitake beta-glucan induced G-CSF in human umbilical 
cord blood monocytes stimulating colony-forming unit-
granulocyte/macrophage (CFU-GM) differentiation in cir-
culating hematopoietic progenitors [18], we hypothesized 
that Maitake would be effective in MDS.
Maitake extract, derived from the fruit body of the edi-
ble mushroom Grifola frondosa, contains beta-glucans with 
a 1,6-glucan main chain and 1,3-branches [19]. Maitake 
beta-glucan does not show direct cytotoxic or cytocidal 
activity, but inhibited lung metastasis when given by intra-
peritoneal injection (i.p.), enhancing IL-12 production 
and activating natural killer cells [20]. Maitake increased 
messenger ribonucleic acid expression of GM-CSF, 
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G-CSF, M-CSF, interferon, and IL-12 p40, and attenuated 
decrease in CFU-GM colonies of cisplatin-treated mice 
[21]. Maitake had dose-dependent hematopoietic effects 
on mouse bone marrow cells in vitro, protecting CFU-GM 
progenitor cells from doxorubicin toxicity [22]. Ito et al. 
[23] recently showed that Maitake enhanced granulopoiesis 
and mobilized granulocytes and progenitors by stimulating 
G-CSF production in cyclophosphamide-induced granulo-
cytic mice. Lin et al. [24] showed that oral Maitake stimu-
lated homing and engraftment of transplanted donor cord 
blood cells into recipient mice, while Ito et al. [23] dem-
onstrated that Maitake administered i.p. caused downregu-
lation of chemokine receptor CXCR4, and the ligand stro-
mal-derived factor-1 in the bone marrow of granulocytic 
mice, causing granulocyte mobilization. Maitake appears 
to enhance differentiation and migration of hematopoietic 
cells including progenitors and thereby enhances peripheral 
myeloid cell ROS function.
In our previous dose-escalation trial, breast cancer 
patients receiving Maitake extract orally at 5–7 mg/kg daily 
over 3 weeks showed significant dose-related changes in 
immune function with no serious adverse events or dose-
limiting toxicity [25]. Based on these dose effects, the pre-
sent study was launched using Maitake extract at 6 mg/kg 
(i.e., 3 mg/kg twice daily), to assess neutrophil and mono-
cyte function in MDS patients.
Methods
Patients
This phase II, open-label, non-randomized, safety, and effi-
cacy trial enrolled MDS patients with IPSS low- or inter-
mediate-1-risk disease who met criteria for MDS based 
on the FAB and World Health Organization classification 
systems [26, 27]. Additional eligibility criteria included age 
≥18 years, ability to sign informed consent, bone marrow 
blasts ≤10 %, absolute neutrophil count (ANC) ≥0.5 K/
mcL, and stable disease without history of recurrent infec-
tions, treatment with a hypomethylating or other disease-
modifying agent, or prior stem cell transplant. Exclusion 
criteria included history of AML, known human immuno-
deficiency virus (HIV) infection or allergy to mushrooms. 
The Memorial Sloan Kettering Cancer Center (MSKCC) 
Institutional Review Board approved the study. Patients 
were enrolled after informed consent was obtained by the 
Leukemia Service at MSKCC.
Endpoints
Primary efficacy endpoints were ANC and neutrophil func-
tion as measured by changes in respiratory burst response. 
Changes in neutrophil count were described using the 
International Working Group (IWG) modified response cri-
teria for MDS [28].
Secondary efficacy endpoints included changes in hemo-
globin, platelet, and reticulocyte counts; G-CSF and GM-
CSF levels, monocyte function as measured by respiratory 
burst response, and iron studies in part because beta-glu-
cans are susceptible to free-radical degradation [29].
Safety was assessed with serial blood chemistry panels 
and symptom assessment, performed at baseline and study 
visits at weeks 1, 3, 7, 9, and 12. Adverse events were sum-
marized by grade defined by Common Terminology Crite-
ria for Adverse Events (CTCAE) version 4.0 [30].
Study protocol
Following double baseline evaluation (1 week apart) 
for hematologic parameters, immune function studies, 
and symptom assessment, patients were instructed to 
take Maitake extract (3 mg/kg) twice daily by mouth for 
12 weeks [25]. Symptom assessment, hematologic param-
eters, and immune studies were performed at two base-
line visits and during treatment weeks 1, 3, 7, 9, and 12. 
Measures specific only to the first baseline visit included 
complete blood count and reticulocyte counts, iron status 
(serum iron, ferritin, and total iron-binding capacity), and 
chemistry panel. Iron status and chemistry panel studies 
were repeated at week 7 and week 12. Blood samples from 
healthy volunteers were assessed in parallel with patients’ 
immune studies over the 2-year study period. Data col-
lected over the 12-week period of Maitake consumption 
were compiled and compared with baseline studies.
Healthy controls (HC)
We compared the results of immune function studies in the 
MDS patients to age-matched healthy volunteers, to con-
trol for the possibility of waning age-related immune func-
tion in our MDS cohort (median age, 70). Volunteers were 
recruited through study flyers with assistance from the 
MSKCC volunteer office. Inclusion criteria were healthy 
individuals ≥55 years of age. Exclusion criteria were cur-
rent use of corticosteroids or other immunosuppressants, 
known history of HIV infection, current or previous his-
tory of malignant disorder except adequately treated non-
melanoma skin cancer, curatively treated in situ cancer of 
the cervix, or other solid tumors curatively treated with no 
evidence of disease for >3 years.
Intracellular ROS activity
Neutrophil and monocyte function was measured on freshly 
drawn anticoagulated blood from patients and volunteers in 
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the Weill-Cornell Cellular Immunology laboratory. Endog-
enous and activated intracellular ROS production was assessed 
by flow cytometry as previously described [17, 31]. Activators 
were as follows: opsonized Escherichia coli, a physiologic, 
whole bacterial particulate stimulus that signals through Toll-
Like Receptor 4, the lipopolysaccharide (LPS) receptor; PMA, 
a membrane-soluble signal that bypasses receptor binding, 
measures capacity for ROS production, and requires an intact 
NADPH oxidase system; and fMLP. Aliquots of heparinized 
whole blood from study subjects and HC were mixed with 
or without activators (Phagoburst, Orpegen Pharma, Heidel-
berg, Germany) and briefly incubated at 37 °C. Addition of 
the fluorogenic substrate dihydrorhodamine (DHR-123) was 
used to detect formation of reactive oxidants after conversion 
to rhodamine-123. Red cells were removed by lysis and cells 
were partially fixed. DNA stain was added. Flow cytometric 
evaluation of respiratory burst activity was performed (FACS-
Calibur, Becton–Dickinson, San Jose, California), using Cell-
Quest software for acquisition and FlowJo software (Tree Star, 
Ashland, Oregon) for analysis of the percentage of gated gran-
ulocyte and monocyte populations producing ROS and rela-
tive amounts by geometric mean fluorescence in each sample.
Serum GM-CSF and G-CSF
Blood samples were collected at each visit, and serum was 
obtained and frozen at −80 °C in multiple aliquots for each 
patient pending analysis by enzyme-linked immunosorbent 
assay. Due to a freezer malfunction, all the samples were 
inadvertently thawed and were not evaluated.
Maitake extract
Maitake mushroom (G. frondosa) liquid extract was prepared 
from raw mushroom cultivated in controlled facilities (Yuki-
guni Maitake Company Ltd., Japan). After harvesting, the fruit-
ing body was extracted with hot water and alcohol and dried to 
powder form (Nanba et al. [19], U.S. Patent # 5,854,404) and 
tested for contaminants including endotoxin (Limulus ame-
bocyte lysate assay). Glycosyl composition analysis [32] and 
stimulation of G-CSF production were used as quality control 
markers [18]. The powder was dissolved in glycerin for liquid 
formulation to yield a concentration of 40 mg/mL (Yellow 
Emperor Inc., Eugene, Oregon) via the distributor (Tradeworks 
Group, Brattleboro, Vermont). Manufacturing and control 
methods were filed with the US Food and Drug Administration 
under Investigational New Drug #68853.
Statistical methods
The sample size was based on published data of neutrophil 
count, 1,200/mm3 (SD 600/mm3) [33–35]. A study with 20 
evaluable patients would have a confidence interval (CI) 
around the change in neutrophil counts at 12 weeks of 
±270/mm3. Baseline values for the neutrophil and mono-
cyte count and function tests were calculated as the average 
of values between first and second baseline assessments. 
Percent change was calculated as the difference between 
the value at 12 weeks and baseline, divided by the baseline 
value and multiplied by 100. A one-sample t test was used 
to evaluate whether the change between raw score at base-
line and raw score at 12 weeks was equal to zero.
The protocol suggested the use of analysis of variance 
(ANOVA) to test whether the means of the baseline neu-
trophil function tests and means of the baseline monocyte 
function tests were equal between HC and MDS patients 
receiving Maitake mushroom extract. However, due to the 
non-normal distribution in these groups, a rank sum test was 
used as the principal method of analysis. Although we con-
sidered age as a potential confounder, it was not included as 
a variable in the analysis due to the small sample size.
A subgroup analysis was performed on MDS ROS 
responses at baseline, weeks 1–3, and weeks 7–12 by 
repeated measures ANOVA (Prism 5.0). If significant over-
all variance was found, Tukey’s posttest was used to deter-
mine significance of pairwise comparisons. MDS patients’ 
data were grouped and evaluated as: baseline: repeated val-
ues from 2 pre-treatment studies; weeks 1–3: repeated values 
comprising 2 sets of studies at weeks 1 and 3; weeks 7–12: 
repeated values comprising 3 sets of studies at weeks 7, 9, 
and 12. For HC, all values were in a single group and data for 
the 4 patients with 2 studies were treated as repeated values.
Results
MDS patient population characteristics
Between April 2010 and June 2012, 23 patients met eligi-
bility criteria and gave informed consent for the study. Two 
patients were removed during the double baseline screening 
period for having ANC values ≤0.5 at the second screen-
ing with an ANC >0.5 at initial screening, and 21 patients 
received Maitake extract (Fig. 1). Baseline patient char-
acteristics are summarized in Table 1. The median age of 
70 years is consistent with MDS diagnosis in the USA [36]. 
The time between diagnosis and study entry (approximately 
2 years) allowed for adequate pre-treatment assessment of 
disease stability. MDS subtypes are summarized in Table 1.
Patient disposition
A total of 18 patients, 7 women and 11 men, completed 
the planned 12-week treatment and were evaluable. One 
patient withdrew due to CTCAE 4.0 grade 1 diarrhea, and 
2 other patients were removed due to disease progression. 
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One patient with chronic myelomonocytic leukemia at 
baseline abruptly progressed to AML after 3 weeks of 
study medication and expired 2 weeks later. Another patient 
was removed by the treating physician due to persistent, 
although not worsening, leukopenia and the decision to try 
aggressive treatment. Leukopenia preceded Maitake treat-
ment and was evaluated as probably unrelated.
Toxicity
Maitake was generally well tolerated. CTCAE 4.0 grade 1 eosin-
ophilia was noted in 4 patients, and two of these patients also 
experienced grade 1 diarrhea. One patient experienced grade 1 
nausea. One patient with grade 1 diarrhea withdrew consent due 
to the persistent, albeit low-grade nature of the diarrhea.
Baseline pre-treatment hematologic parameters
Compared with the normal range neutrophil values from 
MSKCC Clinical Laboratories, 14 (78 %) patients were 
normal and 4 patients had a low ANC (<1.5 K/mcL) at 
baseline. Most patients had normal levels of monocytes, 
neutrophils, and lymphocytes, but 10 (56 %) had a low 
white blood cell (WBC) count (<4 K/mcL). Three patients 
had low neutrophil counts with normal monocyte and lym-
phocyte counts; one patient had a low neutrophil count, nor-
mal lymphocyte count, and high monocyte count (>1.3 K/
mcL); one patient had normal neutrophil and monocyte 
counts and a low lymphocyte count (<0.5 K/mcL); five 
patients had a low WBC (<4 K/mcL) with normal neutro-
phil, monocyte, and lymphocyte counts (Table 2).
Baseline Intracellular ROS activity in MDS patients
Baseline analysis was carried out using pre-treatment sam-
ples from 17 patients. Due to insufficient gated events, one 
MDS patient’s blood sample was excluded. There was no 
significant difference in neutrophil and monocyte endog-
enous intracellular ROS production when baseline values 
of MDS patients were compared with HC (Table 3). ROS 
Fig. 1  Patient flow diagram, 
from time of enrollment to com-
pletion of study or withdrawal
Excluded (n=479)
• Inclusion criteria not met (n=445)*
7 ANC <0.5 K/mcL
76 Candidate for aggressive treatment
7 IPSS High- or Intermediate-2-risk
6 History (Hx) of AML
31 Hx of/eligible for stem cell transplant 
2 HIV positive
9 Bone marrow blasts >10% 
31 Other concurrent cancer
143 Possible/no definitive MDS diagnosis 
66 Live too far away/study logistics
120 Deceased/other
• Declined to participate (n=34)
*Totals do not equal 445 because patients were 
deemed ineligible by >1 inclusion criteria.
Evaluable patients (n=18)
• fMLP (n=17): Due to insufficient gated 
events in lab samples, only 17 patients were 
included for neutrophil and monocyte fMLP 
in baseline and 12-week analysis. 
Treatment discontinued (n=3)
• Adverse events (n=1)
• Disease progression (n=2)
Enrolled to treatment (n=23)
Did not receive treatment (n=2)
• Low baseline ANC
Received treatment (n=21)
Assessed for eligibility (n=502)
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response to fMLP and PMA were also comparable for 
MDS and HC. In contrast MDS patients’ monocytes dem-
onstrated a significantly lower ROS response to E. coli 
stimulation compared with HC (mean difference −14.3; 
95 % CI −21.1, −7.4; p = 0.002; Table 3).
Effect of Maitake treatment on hematologic parameters
Most study patients had normal neutrophil counts at 
baseline. When total neutrophil and monocyte counts 
were examined over time, no patient met IWG criteria 
for Hematologic Improvement, although three patients 
showed transient increases in ANC values that were not 
sustained. Mean monocyte count (Table 3) was not signifi-
cantly increased at 12 weeks. A treatment-related decrease 
in mean neutrophil count (−0.3; 95 % CI −0.5, 0.0; 
p = 0.044) was not clinically meaningful (Table 3). A small 
significant decrease in mean hemoglobin, correlating with 
changes in hematocrit and red blood cell (RBC) count, was 
observed from 11.5 (±1.4) to 11.0 (±1.4) g/dL as shown 
in Table 2. Mean corpuscular hemoglobin did not decrease 
(data not shown). No patient became anemic (Hgb < 9 g/
dL). The significant increase in mean eosinophil count 
(1.37 K/mcL; p = 0.011) was considered CTCAE Grade 1, 
while basophil count was unchanged (Table 2).
Effect of Maitake treatment on ROS activity in MDS 
patients
After 12 weeks of Maitake treatment, MDS patients 
showed an overall increase in mean endogenous neutro-
phil ROS production ex vivo, indicating enhanced basal 
function (3.2; 95 % CI 1.3, 5.1; p = 0.005; Table 3). Basal 
monocyte function also increased at 12 weeks compared 
with pre-treatment levels (p = 0.021). Stimulated ROS pro-
duction in monocytes increased in response to both E. coli 
(p = 0.0004) and fMLP (p = 0.03). Response to PMA did 
not change in either cell type, and neutrophil responses to 
fMLP and E. coli were not affected. These responses were 
comparable with those of HC at baseline. Figure 2 shows a 
histogram of pre- and post-treatment monocyte responses 
to fMLP, PMA, and E. coli in a single patient compared 
with endogenous activity at one baseline visit and again 
at 12 weeks. Individual MDS patients showed variable 
changes over the 5 treatment week visits. Figure 3 shows 
MDS monocyte responses to fMLP and to E. coli at pre-
treatment baseline visits, at weeks 1–3, and at weeks 7–12 
compared with HC (see Methods). MDS patient monocytes 
stimulated with fMLP showed increased ROS activity at 
weeks 7–12 compared with baseline (p < 0.01) and with 
HC (p < 0.05) by repeated measures ANOVA and Tukey’s 
posttest. Response to E. coli was reduced compared with 
HC at baseline, but not at 12 weeks (Table 3). Repeated 
measures by ANOVA and Tukey’s posttest also show an 
increase at weeks 7–12 in MDS patients compared with 
baseline (p < 0.05).
Discussion
Infections are the most common cause of death in patients 
with lower-risk MDS [2]. Although antibacterial and anti-
fungal prophylaxis may be employed, the efficacies are 
limited [1]. We have previously shown that Maitake beta-
glucan promotes maturation of hematopoietic progenitor 
cells (HPC) in vitro and enhances the recovery of periph-
eral blood leukocyte numbers and ROS function after 
chemotoxic bone marrow injury in vivo [17, 18]. The pre-
sent study examined the effects of oral Maitake extract 
treatment on peripheral blood neutrophil and monocyte 
function in untreated, lower-risk MDS patients.
Table 1  Baseline characteristics of evaluable MDS patients (n = 18)
Results are presented as median (interquartile range [IQR]) or fre-
quency. Some totals exceed 100 % due to rounding
CMML chronic myelomonocytic leukemia, RAEB-1 refractory ane-
mia with excess blasts (EB), -1: cytopenias < 5 % blasts, no Auer 
rods, < 1 × 109/L monocytes in peripheral blood, RARS RA with 
ringed sideroblasts (RS), RC refractory cytopenia, RCMD RC with 
multilineage dysplasia (MD), RCUD RC with unilineage dysplasia 
(UD)
Patient characteristics
Male 11 (61 %)
Age 70 (64, 75)
Race
White 16 (89 %)
Black 1 (6 %)
Other 1 (6 %)
Time from diagnosis to study consent (year) 2.3 (1.4, 4.4)
ECOG performance status
Fully active (0) 9 (50 %)
Restricted from physically strenuous activity (1) 9 (50 %)
Bone marrow biopsy karyotype
Normal 9 (50 %)
11q deletion 2 (11 %)
20q deletion 5 (28 %)
Trisomy 8 1 (6 %)
Trisomy 1 1 (6 %)
MDS classification
RCMD 10 (56 %)
RARS 2 (11 %)
RCMD-RS 2 (11 %)
RCUD 2 (11 %)
CMML 1 (6 %)
RAEB-1 1 (6 %)
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Table 2  Mean change in complete chemistry panel values between baseline and 12 weeks in evaluable MDS patients, n = 18
Test (units) Mean (SD) at Baseline Mean (SD) at 12 Weeks Mean change (95 % CI) p value
Albumin (g/dL) 4.5 (0.2) 4.3 (0.3) −0.2 (−0.2, −0.1) 0.001
Alkaline phosphatase (U/L) 67.2 (26.1) 68.1 (24.3) 0.9 (−2.5, 4.3) 0.6
Alkaline aminotransferase (U/L) 28.6 (12.8) 26.4 (13.7) −2.2 (−8.0, 3.5) 0.4
AST (U/L) 29.5 (10.5) 28.1 (13.6) −1.4 (−5.3, 2.6) 0.5
Basophils (K/mcL) (n = 14) 0.7 (0.4) 0.7 (0.3) 0.0 (−0.1, 0.1) 0.8
Bilirubin (mg/dL) 0.7 (0.4) 0.7 (0.3) 0.0 (−0.1, 0.1) 0.8
BUN (mg/dL) 18.7 (5.0) 19.0 (6.4) 0.3 (−1.9, 2.4) 0.8
Calcium (mEq/dL) 9.4 (0.5) 9.2 (0.5) −0.2 (−0.4, 0.1) 0.2
Chloride (mEq/L) 106.2 (3.1) 105.7 (2.9) −0.5 (−2.1, 1.1) 0.5
CO2 (mEq/L) 28.9 (2.6) 28.2 (2.1) −0.7 (−2.0, 0.6) 0.3
Eosinophil (K/mcL) (n = 14) 2.5 (1.4) 3.9 (2.4) 1.4 (0.4, 2.5) 0.011
Total iron (mcg/dL) 121.6 (47) 129.8 (68.1) 8.2 (−17.9, 34.3) 0.5
Ferritin (ng/mL) 225.6 (296.5) 192.2 (203.5) −33.4 (−118.2, 51.4) 0.4
Glucose (mg/dL) 111.2 (47.5) 123.4 (51.1) 12.2 (−1.9, 26.3) 0.086
Hemoglobin (g/dL) 11.5 (1.4) 11.0 (1.7) −0.5 (−0.8, −0.2) 0.003
Hematocrit 34.1 (4.1) 33.0 (4.7) −1.1 (−2.0, −0.3) 0.012
Iron-binding capacity (mcg/dL) (n = 17) 327.8 (72.8) 328.1 (84.1) 0.2 (−16.8, 17.3) >0.9
Potassium (mEq/L) 4.5 (0.4) 4.3 (0.2) −0.1 (−0.3, 0.1) 0.2
Lymphocytes (K/mcL) 32.3 (11.5) 33.8 (12.6) 1.5 (−1.1, 4.1) 0.2
Sodium (mEq/L) 141.6 (1.7) 140.6 (2.0) −1.1 (−2.3, 0.2) 0.082
Red blood cell count 3.6 (0.7) 3.4 (0.7) −0.1 (−0.2, 0.0) 0.025
Reticulocytes (%) 2.4 (1.5) 2.3 (1.6) −0.1 (−0.5, 0.4) 0.8
Total protein (g/dL) 7.2 (0.5) 7.0 (0.5) −0.2 (−0.3, −0.1) 0.001
Platelet counts (K/mcL) 148.0 (106.9) 146.3 (100.3) −1.7 (−11.9, 8.4) 0.7
White blood cell count (K/mcL) 3.9 (2.1) 3.7 (2.4) −0.2 (−0.5, 0.2) 0.4
Table 3  Mean (SD) baseline neutrophil and monocyte count and function in evaluable MDS patients and HC and mean change between base-
line and 12 weeks in evaluable MDS patients, n = 18
Healthy controls  
(n = 18)
MDS patients at  
baseline (n = 18)
MDS patients at  
12 weeks (n = 18)
Mean difference  
between HC and  
MDS patients at  
baseline (95 % CI)
p Change from base 
line to 12 weeks 
in MDS patients  
(95 % CI)
p
Neutrophil count – 2.0 (1.0) 1.7 (1.0) – – −0.3 (−0.5, 0.0) 0.044
Neutrophil function
Unstimulated 5.1 (3) 4.1 (3.1) 7.3 (6.3) −1.0 (−3.0, 1.0) 0.2 3.2 (1.3, 5.1) 0.005
E. coli 95.5 (2.4) 90 (10.1) 93.5 (10.5) −5.5 (−10.3, −0.8) 0.4 3.5 (−3.7, 10.7) 0.4
fMLP (n = 17) 11.8 (5.3) 9.6 (5.0) 12.9 (8.4) −2.1 (−5.5, 1.3) 0.2 3.2 (−0.5, 7) 0.11
PMA 96.6 (4.3) 94.2 (7.0) 96.8 (5.1) −2.4 (−6.2, 1.4) 0.2 2.6 (−1.0, 6.2) 0.2
Monocyte count – 11.4 (9.9) 12.1 (11.3) – – 0.7 (−1.4, 2.8) 0.5
Monocyte function
Unstimulated 5.3 (5.4) 2.8 (2.4) 6.7 (6.2) −2.4 (−5.2, 0.4) 0.2 3.9 (0.9, 6.9) 0.021
E. coli 89 (4.2) 74.7 (14.5) 85.1 (14.0) −14.3 (−21.1, −7.4) 0.002 10.4 (5.9, 14.9) 0.0004
fMLP (n = 17) 10.7 (7.3) 9.7 (6.5) 17.9 (13.0) −1.0 (−5.5, 3.6) 0.7 8.2 (1.5, 14.9) 0.030
PMA 95.9 (4.1) 86.3 (14.9) 91.9 (10.0) −9.6 (−16.8, −2.5) 0.10 5.7 (0.0, 11.3) 0.068
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Impaired host defense in MDS is associated with func-
tional defects in the myeloid lineage including HPC and 
presents as aberrant functioning and has selective effects in 
host defense mechanisms [9, 12]. Neutrophil and monocyte 
production of ROS during the respiratory burst is essential 
for bactericidal activity. Prodan et al. [12] using a similar 
whole blood flow cytometric assay reported that defects in 
both monocyte and neutrophil ROS production were char-
acteristic of MDS patients, independent of neutrophil num-
bers, and worsened with more advanced disease. Fianchi 
et al. [7] have reported that isolated neutrophils displayed 
reduced microbicidal activity, explaining the high fre-
quency of recurrent infections in MDS patients who were 
not neutropenic. They demonstrated progressive loss of 
Fig. 2  Histogram of pre- and post-treatment monocyte responses. 
Flow cytometry data for one representative patient shows the percent-
age of monocytes producing ROS after incubation of peripheral blood 
with fMLP, opsonized E. coli, or PMA compared with the parallel, 
unstimulated culture assessed ex vivo at baseline and at 12 weeks. 
Initial gating was performed on populations of monocytes (as distinct 
from lymphocytes and granulocytes) in the unstimulated cultures 
using CellQuest software to establish parameters for forward versus 
side light scatter gating. ROS activity in the unstimulated culture con-
dition was then determined by detection of rhodamine fluorescence in 
the same physically gated population using the FL-1 channel (fluo-
rescein isothiocyanate, FITC) parameter. Monocyte ROS responses 
to fMLP, E. coli, and PMA on each date were compared with their 
unstimulated response by detection of FL-1 fluorescence in the com-
parable physical population defined in the parallel unstimulated cul-
ture before and after Maitake treatment using FlowJo software to 
apply the same gate to the culture set
Fig. 3  Effect of oral Maitake extract in vivo on respiratory burst 
activity (ROS) and in vitro in MDS patients. Data show changes in 
the monocyte ROS function over the study period compared with 
baseline levels and HC responses. MDS patient monocytes showed 
increased ROS activity compared with their baseline levels for fMLP 
(top panel) and for E. coli (bottom panel). Baseline levels were lower 
in MDS patients compared with HC for E. coli, but not different from 
HC at 7–12 weeks as shown
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microbicidal activity against gram-negative E. coli, but not 
gram-positive lactobacilli or fungus (Candida albicans) 
over the course of monthly studies in patients compared 
with corresponding functions at diagnosis, suggesting that 
immune dysfunction in MDS may be pathogen-specific and 
involve selective host defense pathways.
Our results demonstrate for the first time that monocyte 
ROS response to physiological E. coli is reduced in lower-
risk MDS patients, but could be restored after 12 weeks of 
Maitake treatment. Furthermore, monocyte ROS response 
to fMLP, the bacterial peptide analogue, was signifi-
cantly increased. Both neutrophils and monocytes showed 
increased basal production of ROS after Maitake treat-
ment. Recent studies show that LPS from E. coli activates 
neutrophils to prime monocyte ROS production, leading 
to release of proinflammatory cytokines and further prim-
ing of neutrophils [37, 38]. Our data therefore suggest that 
monocyte ROS dysfunction may be an early marker of 
impaired microbicidal activity due to defective monocyte–
neutrophil interaction. Maitake has been shown to stimu-
late human neutrophil phagocytosis in vitro [39].
Endogenous ROS production is necessary to maintain 
basal activity and is regulated by cytokines and the growth 
factors GM-CSF and G-CSF. Our observation that MDS 
patients showed increased neutrophil ROS response after 
Maitake treatment suggests that G-CSF induction in bone 
marrow leads to HPC maturation and release of more func-
tionally competent cells [18].
We did plan to measure serum G-CSF (and GM-CSF 
for comparison) on an exploratory basis but were unable 
to perform the experiment due to concerns about specimen 
integrity after freezer malfunction. In our breast cancer trial 
with oral Maitake beta-glucan [25], we assessed circulating 
levels of G-CSF in a subset of 6 patients comparing dou-
ble baseline levels with 3 follow-up visits over a 12-week 
period. All patients showed positive or elevated G-CSF 
at baseline visits (11–80 pg/mL). While marked changes 
occurred in some, differences between baseline and post-
treatment were not significant (Cunningham-Rundles and 
Lin, unpublished data).
Others have reported that ROS are higher in RBCs but 
not in neutrophils in MDS patients, compared with nor-
mal cells. Moreover, increased ROS in RBCs from MDS 
patients correlated with increased serum ferritin due to iron 
accumulation [14, 40]. Although serum ferritin levels did 
not change during our study, it is possible that Maitake 
does not increase RBC ROS or that a longer treatment 
period is needed to produce an increase in ferritin levels.
Maitake extract appeared to be safe in this MDS popu-
lation. We found no evidence of altered disease activity or 
progression. Mild eosinophilia was noted in four patients, 
including one patient with associated diarrhea. The etiol-
ogy and clinical significance of peripheral eosinophilia 
in this context is unclear and could have been an allergic 
reaction to the mushroom [41]. Eosinophilia and basophilia 
together predicted reduced survival without affecting leu-
kemia-free survival in intermediate-2-risk MDS patients 
[42]. No patient in our study showed increased basophils.
Our study has some limitations, including single-
arm design and the potential for patients to have similar 
improvements without the intervention. A future study with 
a non-treatment control arm is needed to rule this out. In 
addition, due to the number of tests performed, it is possi-
ble that some changes between baseline and 12 weeks were 
due solely to chance, although this type of effect would 
also have affected the double baseline values and should 
have reduced detection of treatment differences.
Conclusions
Maitake beta-glucan consumption improves neutrophil 
and monocyte function in lower-risk MDS patients. The 
enhanced ROS response to E. coli ex vivo in response 
to Maitake extract treatment suggests that Maitake may 
enhance immune responses against bacterial infection in 
MDS patients. A larger study of longer duration will be 
required to see if these observed effects will translate into 
decreased rates of infection.
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